Related Experiment Video
Updated: Jan 7, 2026
07:58
Formulation and Characterization of Bioactive Agent Containing Nanodisks
Published on: March 17, 2023
1.6K
Cardiolipin-Based Nanoparticles Inhibit α-Synuclein Fibrilization
Morgan G Stykel1, Justin Medeiros1, Tammy L Ryan2
1Department of Molecular and Cellular Biology, The University of Guelph, Guelph, ON N1G 2W1, Canada.
ACS Chemical Neuroscience
|December 26, 2025
Summary
Cardiolipin nanoparticles reverse alpha-synuclein (α-syn) misfolding in synucleinopathies. These nanoparticles dissolve α-syn aggregates, protecting dopamine neurons from cell death and offering a potential therapeutic strategy.
Area of Science:
- Neuroscience
- Biochemistry
- Nanotechnology
Background:
- Synucleinopathies involve alpha-synuclein (α-syn) misfolding and aggregation.
- α-syn accumulation forms intracellular inclusions, leading to neuronal death.
Purpose of the Study:
- Investigate cardiolipin (CL)-based nanoparticles for reversing α-syn fibrillization.
- Assess the potential of CL-nanoparticles to rescue dopamine neuron loss.
Main Methods:
- Circular dichroism (CD) and transmission electron microscopy (TEM) analyzed α-syn structural changes.
- Functional assessments were performed in rodent models of synucleinopathy.
Main Results:
- CL-nanoparticles induced structural refolding of fibrillar α-syn to an α-helical form.
- Nanoparticles dissolved α-syn aggregates and prevented cell death in models.
Conclusions:
- CL-based nanoparticles demonstrate capacity to mitigate synucleinopathy progression.
- This approach offers a novel therapeutic avenue for neurodegenerative disorders.
